Q-omics provides the consensus-scored FRG2B profile across patient tissues and cancer cell-line models. FRG2B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FRG2B is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FRG2B RNA expression shows 7,634 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where FRG2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRG2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRG2B survival associations across molecular data types. FRG2B RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRG2B RNA expression–survival associations across cancer types. High FRG2B expression shows unfavorable associations in COAD, ESCA, PCPG, LUAD and THYM, but favorable associations in SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for FRG2B RNA expression.
This table summarizes FRG2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FRG2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRG2B shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LUAD, HNSC and LIHC. The KIRC box plot shows higher FRG2B RNA expression in normal versus tumor tissue (log2 FC = −0.571, t-test p < 0.001).
This table shows molecular features associated with FRG2B in patient tissues and cancer cell lines. In patient samples, FRG2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRG2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
